Search clinical trials for: Sorafenib Escalated Dose

Total 7049 results

Bayer

Completed

Regulatory Post Marketing Surveillance Study on Nexavar®

Carcinoma, Renal Cell | Carcinoma, Hepatocellular

Korea, Republic of
Bayer

Completed

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Carcinoma, Hepatocellular

Japan
Bayer

Completed

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

Belgium, Italy, Spain, Germany, France, Netherlands, Switzerland, Poland, Sweden, United Kingdom, Denmark
Bayer

Terminated

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Carcinoma, Renal Cell

United States
Bayer

Completed

INSIGHT - Post Marketing Surveillance (INSIGHT)

Carcinoma, Hepatocellular

Germany, Austria
Bayer

Completed

Sorafenib Gastric Cancer Asian Phase I Study

Gastric Cancer

Japan
Bayer
Amgen

Completed

Sorafenib/Docetaxel Dose Escalation Trial

Neoplasms

United States
Menarini Group

Completed

Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride (DAVID lap)

Acute Pain

Romania, Poland, Hungary, Latvia, Lithuania, Russian Federation, Slovakia, Spain
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer

Prostate Cancer

United States
Bayer
Amgen

Completed

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Carcinoma, Renal Cell

United States, United Kingdom
Bayer

Completed

Hepatic Impairment Study

Liver Disease

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States
Bayer

Completed

BAY43-9006 - Phase II in Advanced Breast Cancer

Breast Cancer | Breast Neoplasms

Italy, Germany
Institute of Liver and Biliary Sciences, India

Completed

Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

India
National Cancer Institute (NCI)

Completed

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

Advanced Malignant Neoplasm

United States
University of Texas Southwestern Medical Center

Completed

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

Hepatocellular Carcinoma | Liver Cancer

United States
Gesellschaft fur Medizinische Innovation - Hamatologie...
iOMEDICO AG

Completed

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment (PASO)

Metastatic Breast Cancer

Germany
Yamagata University

Unknown

Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma (CROSS-J-RCC)

Metastatic Renal Cell Carcinoma

Japan
Bayer

Completed

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Belgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
Asan Medical Center
Bayer

Unknown

Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) (COTSOM)

Hepatocellular Carcinoma | Metastasis

Korea, Republic of
Bayer
Amgen

Completed

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

Italy, Spain, Canada, United States, Russian Federation, France, Australia, Chile, Germany, Hungary, Israel, United Kingdom, South Africa, Poland, Netherlands, Belgium, Ukraine, Argentina, Brazil
Bayer

Completed

Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. (BASIL)

Carcinoma, Hepatocellular

Hong Kong, Taiwan, Korea, Republic of, Singapore
ZymoGenetics

Completed

Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
Southern Europe New Drug Organization
Bayer; Novartis

Suspended

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Advanced Solid Tumors

Italy
Sinocelltech Ltd.

Active, not recruiting

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Mina Alpha Limited

Active, not recruiting

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH)

Hepatocellular Carcinoma | Liver Cancer

Taiwan, Singapore, United Kingdom
Acceleron Pharma Inc. (a wholly owned subsidiary...

Completed

Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Esophageal Cancer | Gastroesophageal Junction Cancer

United States
Bayer
Amgen

Completed

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms

France, China, Korea, Republic of, United States, Spain, Russian Federation, United Kingdom, Netherlands, Sweden, Austria, Italy, Bulgaria, Poland, Saudi Arabia, Germany, Japan, Belgium, Denmark
Bayer

Completed

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

Carcinoma, Renal Cell

Japan
Bayer

Completed

Sorafenib in Elderly mRCC

Carcinoma, Renal Cell

China
Bayer

Completed

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Canada, Singapore, United States, Germany, Australia, Austria, Korea, Republic of, Italy, Taiwan
National Cancer Institute, Naples

Terminated

Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma (BOOST)

Advanced Adult Hepatocellular Carcinoma

Italy
Bayer

Completed

Sorafenib Drug Drug Interaction Study in Healthy Male Subjects

Drug Interactions

Germany
Bayer

Completed

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Ovarian Neoplasms

Poland, Belgium, Spain, Hong Kong, Korea, Republic of, Canada, Italy, Singapore, Germany, United States, Netherlands, France, Japan, Finland
Bayer

Completed

Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma (NEXTAR)

Carcinoma, Renal Cell

Germany
Cancer Trials Ireland

Completed

Sorafenib. ICORG 06-41, V4

Gastric Cancer | Esophageal Cancer

Ireland
Bayer

Completed

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (ORACLE)

Chronic Myelogenous Leukemia

United States, France
Bayer

Completed

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Istituto Clinico Humanitas

Completed

Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Carcinoma, Hepatocellular

Italy
Centre Oscar Lambret

Unknown

Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery

Sarcoma

France
Italian Trial in Medical Oncology

Completed

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) (ROSORC)

Renal Cell Carcinoma | Metastatic Disease

Italy
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Hilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditions

United States
Bayer

Completed

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (STORM)

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Hong Kong, United States, Canada, Switzerland, Germany, Portugal, Taiwan, Japan, Russian Federation, Singapore, Austria, United Kingdom, Korea, Republic of, Australia, New Zealand, Mexico, Brazil, Italy and more
Emory University
OSI Pharmaceuticals

Terminated

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Liver Cancer

United States
Southwest Hospital, China

Unknown

Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC

HCC

China
Bayer

Completed

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Belgium, Israel, Italy, France, United States
Bayer

Terminated

Research Study for Patients With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States

Search clinical trials for: Sorafenib Escalated Dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations